2020 ASCO Virtual Direct™ Highlights


 

2020 ASCO Update on Targeted Therapies for NSCLC: Clinical Activity of T-Dxd in HER2 Mutated NSCLC & Feasibility of Osimertinib/Gefitinib Combination in EGFR-mutated Disease

289 views
July 13, 2020
Comments 0
Login to view comments. Click here to Login